RecruitingNCT07864870SAGESUpdated Oct 8, 2026

Sarcoma Care Adherence and Survival in Strasbourg

An observational study in Soft Tissue Sarcoma (STS), sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by University Hospital, Strasbourg, France · Observational

From the registry’s dates

Started Nov 2025; still recruiting 10 months later.

Updated Oct 8, 2026Newly registeredGo to Updates ↓

Study type: Observational
Model: Case-only
Time perspective: Retrospective
Enrollment: 900
Ages: 18 Years and older
Sex: All

Study summary

This retrospective monocentric study evaluates adherence to international clinical practice guidelines for soft tissue sarcoma management in Strasbourg and its impact on overall survival. It also compares practices and outcomes between two periods (2010-2016 and 2017-2024).

Conditions studied

Soft Tissue Sarcoma (STS)

Browse trials for

Sarcoma 1,667

Keywords

Sarcoma
Clinical Practice Guidelines
Overall Surviva

In context

Sarcoma

1,667 studies on the registry are indexed under Sarcoma; 393 are open to participants now.

This study's planned enrollment of 900 is above the median of 121 across 238 observational studies indexed under Sarcoma.

Browse Sarcoma studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 968 studies on the registry; 344 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Adult patients with suspected or confirmed soft tissue sarcoma presented at multidisciplinary tumor boards in Strasbourg between 2017 and 2024

Inclusion criteria

Patient aged 18 years or older at first multidisciplinary tumor board presentation
Presented for multidisciplinary tumor board evaluation for soft tissue or visceral tumor
First presentation between 01/01/2017 and 31/12/2024
Absence of opposition to reuse of medical data for research purposes

Exclusion criteria

Exclusion Criteria:

Presence of opposition to reuse of medical data for research purposes
Patient younger than 18 years at first presentation
Bone tumors, gastrointestinal stromal tumors (GIST), or Kaposi sarcoma
First presentation outside the study period
Management outside Alsace-Moselle
Duplicate records

Study design

Observational model: Case-only
Time perspective: Retrospective
Enrollment: 900 participants (estimated)
Patient registry: No

What researchers measure

Primary outcomes

Adherence to Good Clinical Practice and Overall Survival
Evaluation of adherence to international guidelines using DELPHI criteria and assessment of overall survival defined as time from diagnosis to death from any cause
Time frame: From diagnosis up to end of follow-up (2017-2024)

Study locations

1 of 1 sites recruiting

Service d'hématologie-oncologie pédiatrique - CHU de Strasbourg - France
Strasbourg, 67091, France
- Justine Gantzer, MD · Contact · justine.gantzer@chru-strasbourg.fr · 33 3 88 12 88 25
- Justine Gantzer, MD · Principal investigator
- Léopold DESCHARMES, MD · Sub investigator
- François SEVERAC, Statistician · Sub investigator
- Ismael DA SILVA, Statistician · Sub investigator
Recruiting

Updates

1 registry update since Sep 25, 2026

Registered

First appeared on the registry. No changes since

Oct 8, 2026

Show all 1 update

Oct 8, 2026
First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT07864870
Lead sponsor: University Hospital, Strasbourg, France
Responsible party: Sponsor
First posted: Oct 8, 2026
Start date: Nov 27, 2025
Primary completion: Jan 27, 2027 (estimated)
Completion: Mar 27, 2027 (estimated)
Last update: Oct 8, 2026

Study contacts

Justine Gantzer, MD

Contact

justine.gantzer@chru-strasbourg.fr

33 3 88 12 88 25

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Sarcoma→

Other studies from this sponsor

University Hospital, Strasbourg, France

Start the discussion